MYP_153938
Basic Information
Durvalumab
Anticancer
Immunology Immune modulation Immunomodulatory activity
Immunology Immunomodulation Immuno-oncology
Standard
451 amino acids
C2212H3409N589O677S16
Standard
Sequence
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Physicochemical Analysis
49598.31 Da
8.20
3.55
2.63
0.0079
-0.42
0.72
0.01
47.04
68.40
0.0998
83310.00
83935.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0344550 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Mus musculus [Animal]
Monoclonal antibody
9606;10090
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer Immunomodulatory Immuno-oncology
Based on baseline clearance rate, the geometric mean terminal half-life is 18 days.[L12621,L12627]